This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miller, D. Search for Related Content PubMed Articles by Miller, D. Social Bookmarking                         What's this?

Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force

Institute of Neurology, Queen Square, London, WCIN 3BG, UK

In relapsing-remitting and secondary progressive multiple sclerosis (MS), MRI activity on monthly brain scans is a sensitive primary outcome measure in short term exploratory treatment trials. Because conventional MRI findings have a limited correlation with disability, the primary outcome in definitive trials should be clinical, although MRI is useful in providing an index of pathological progression. In trials aimed at preventing evolution from a clinically isolated syndrome to MS, MRI findings should be used in the entry criteria. The likely pathological substrates of irreversible disability are demyelination and axonal loss. Putative MR markers for these pathologies appear to relate more closely to disability than conventional MRI findings. Further technical developments should lead to improved quantitation, pathological specificity and clinical correlations.

Key Words: Multiple sclerosis • treatment trials • MRI

Multiple Sclerosis, Vol. 1, No. 6, 335-338 (1996)
DOI: 10.1177/135245859600100610


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?